Literature DB >> 15389718

Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy).

Joshua M Levine1, Robert A Taylor, Lauren B Elman, Shawn J Bird, Ehud Lavi, Ethan D Stolzenberg, Michael L McGarvey, Arthur K Asbury, Sergio A Jimenez.   

Abstract

Nephrogenic fibrosing dermopathy (NFD), a newly recognized scleroderma-like disease, was originally described as a purely cutaneous disorder. More widespread involvement, including fibrosis of pulmonary and cardiac tissues, has been documented only recently, and it has been suggested that a more appropriate designation is dialysis-associated systemic fibrosis. We report five cases of this novel disorder, spanning a spectrum of primarily skin to primarily muscle involvement. Clinical, radiological, electrophysiological, and pathological studies revealed moderate to severe fibrosis of striated muscles. All patients had end-stage renal failure on chronic dialysis, subacute to chronic hardening of the skin and muscles, restriction of limb movements with joint contractures, but normal to only mildly weak muscle strength. Limitation of movements was caused predominantly by skin tightness and induration, and by joint contractures rather than muscle weakness. Computerized tomography showed fibrosis of the fascia and muscles in the most severely affected patients, and electromyography showed mild to severe myopathic changes. Histopathology of affected muscles revealed a spectrum of mild to severe fibrosis, degenerating fibers, and chronic inflammatory cells. These results further support the contention that NFD is not a purely cutaneous disease, but is part of a larger systemic fibrotic process that may involve muscles.

Entities:  

Mesh:

Year:  2004        PMID: 15389718     DOI: 10.1002/mus.20153

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  22 in total

1.  Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis.

Authors:  Peter J Wermuth; Sergio A Jimenez
Journal:  J Immunol       Date:  2012-05-30       Impact factor: 5.422

2.  Nephrogenic fibrosing dermopathy with involvement of the dura mater.

Authors:  Adam Saenz; Rajni Mandal; Richard Kradin; E Tessa Hedley-Whyte
Journal:  Virchows Arch       Date:  2006-08-02       Impact factor: 4.064

Review 3.  Nephrogenic systemic fibrosis in liver disease: a systematic review.

Authors:  Sameer M Mazhar; Masoud Shiehmorteza; Chad A Kohl; Michael S Middleton; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2009-12       Impact factor: 4.813

4.  Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report.

Authors:  B J Edwards; A E Laumann; B Nardone; F H Miller; J Restaino; D W Raisch; J M McKoy; J A Hammel; K Bhatt; K Bauer; A T Samaras; M J Fisher; C Bull; E Saddleton; S M Belknap; H S Thomsen; E Kanal; S E Cowper; A K Abu Alfa; D P West
Journal:  Br J Radiol       Date:  2014-10       Impact factor: 3.039

5.  Nephrogenic fibrosing dermopathy in children.

Authors:  Ari Auron; Lei Shao; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2006-07-05       Impact factor: 3.714

Review 6.  Nephrogenic systemic fibrosis: an update.

Authors:  Shawn E Cowper; Philip J Boyer
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

7.  Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease.

Authors:  Josef A Schroeder; Christian Weingart; Brigitte Coras; Ingrid Hausser; Stephan Reinhold; Matthias Mack; Volker Seybold; Thomas Vogt; Bernhard Banas; Ferdinand Hofstaedter; Bernhard K Krämer
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 8.237

8.  Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy.

Authors:  Liping Zhang; Xiaonan H Wang; Huiling Wang; Jie Du; William E Mitch
Journal:  J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 10.121

9.  Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents.

Authors:  Peter J Wermuth; Francesco Del Galdo; Sergio A Jiménez
Journal:  Arthritis Rheum       Date:  2009-05

Review 10.  Nephrogenic systemic fibrosis.

Authors:  Diego R Martin
Journal:  Pediatr Radiol       Date:  2007-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.